DICE Therapeutics Key Executives
This section highlights DICE Therapeutics's key executives, including their titles and compensation details.
Find Contacts at DICE Therapeutics
(Showing 0 of )
DICE Therapeutics Earnings
This section highlights DICE Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
$47.55
Stock Price
$2.27B
Market Cap
71
Employees
South San Francisco, CA
Location
Financial Statements
Access annual & quarterly financial statements for DICE Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Revenue | $- | $1.12M | $863.00K | $5.78M |
| Cost of Revenue | $- | $- | $- | $- |
| Gross Profit | $- | $1.12M | $863.00K | $5.78M |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% |
| Research and Development Expenses | $62.56M | $36.51M | $19.58M | $15.71M |
| General and Administrative Expenses | $25.66M | $12.22M | $5.00M | $3.61M |
| Selling and Marketing Expenses | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $25.66M | $12.22M | $5.00M | $3.61M |
| Other Expenses | $- | $- | $- | $- |
| Operating Expenses | $88.22M | $48.73M | $24.58M | $19.32M |
| Cost and Expenses | $88.22M | $48.73M | $24.58M | $19.32M |
| Interest Income | $5.21M | $136.00K | $139.00K | $635.00K |
| Interest Expense | $679.00K | $174.00K | $13.00K | $26.00K |
| Depreciation and Amortization | $5.21M | $136.00K | $836.00K | $1.34M |
| EBITDA | $-83.01M | $-47.47M | $-22.89M | $-12.21M |
| EBITDA Ratio | 0.00% | -4219.29% | -2651.80% | -211.36% |
| Operating Income | $-88.22M | $-47.60M | $-23.72M | $-13.55M |
| Operating Income Ratio | 0.00% | -4231.38% | -2748.67% | -234.58% |
| Total Other Income Expenses Net | $4.33M | $-1.36M | $-18.00K | $609.00K |
| Income Before Tax | $-83.89M | $-48.96M | $-23.74M | $-12.94M |
| Income Before Tax Ratio | 0.00% | -4351.91% | -2750.75% | -224.03% |
| Income Tax Expense | $-2.22M | $-487.00K | $13.00K | $26.00K |
| Net Income | $-81.66M | $-48.47M | $-23.75M | $-12.96M |
| Net Income Ratio | 0.00% | -4308.62% | -2752.26% | -224.48% |
| EPS | $-2.07 | $-3.91 | $-1.02 | $-0.56 |
| EPS Diluted | $-2.07 | $-3.91 | $-1.02 | $-0.56 |
| Weighted Average Shares Outstanding | 39.40M | 12.38M | 23.23M | 23.23M |
| Weighted Average Shares Outstanding Diluted | 39.40M | 12.38M | 23.23M | 23.23M |
| SEC Filing | Source | Source | Source | Source |
| Breakdown | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $1.12M | $- | $188.00K | $225.00K |
| Cost of Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- | $- | $- | $- | $- | $1.12M | $- | $188.00K | $225.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% |
| Research and Development Expenses | $28.20M | $23.66M | $20.09M | $14.73M | $14.33M | $13.41M | $12.21M | $11.69M | $5.98M | $6.62M | $6.06M | $4.46M |
| General and Administrative Expenses | $11.30M | $7.91M | $6.36M | $6.44M | $7.41M | $5.45M | $4.00M | $4.44M | $2.32M | $1.47M | $1.19M | $1.75M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $11.30M | $7.91M | $6.36M | $6.44M | $7.41M | $5.45M | $4.00M | $4.44M | $2.32M | $1.47M | $1.19M | $1.75M |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $39.50M | $31.57M | $26.45M | $21.17M | $21.74M | $18.86M | $16.21M | $16.13M | $8.30M | $8.09M | $7.25M | $6.21M |
| Cost and Expenses | $39.50M | $31.57M | $26.45M | $21.17M | $21.74M | $18.86M | $16.21M | $16.13M | $8.30M | $8.09M | $7.25M | $6.21M |
| Interest Income | $4.68M | $5.93M | $3.70M | $702.00K | $487.00K | $327.00K | $75.00K | $20.00K | $27.00K | $14.00K | $-13.00K | $7.00K |
| Interest Expense | $- | $- | $471.00K | $83.00K | $65.00K | $60.00K | $60.00K | $60.00K | $52.00K | $2.00K | $2.00K | $3.00K |
| Depreciation and Amortization | $687.00K | $5.93M | $3.70M | $1.30M | $1.19M | $519.00K | $156.00K | $146.00K | $179.00K | $180.00K | $172.00K | $169.00K |
| EBITDA | $-34.13M | $-25.65M | $-22.75M | $-19.87M | $-20.56M | $-18.01M | $-16.14M | $-15.97M | $-6.97M | $-7.89M | $-6.90M | $-5.81M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -619.38% | 0.00% | -3672.34% | -2580.44% |
| Operating Income | $-39.50M | $-31.57M | $-26.45M | $-21.17M | $-21.74M | $-18.86M | $-16.21M | $-16.13M | $-7.17M | $-8.09M | $-7.06M | $-5.98M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -637.69% | 0.00% | -3756.91% | -2658.67% |
| Total Other Income Expenses Net | $4.68M | $5.93M | $3.23M | $619.00K | $222.00K | $267.00K | $15.00K | $-1.20M | $-189.00K | $20.00K | $-67.00K | $-34.00K |
| Income Before Tax | $-34.82M | $-25.65M | $-23.22M | $-20.55M | $-21.52M | $-18.59M | $-16.20M | $-17.34M | $-7.36M | $-8.07M | $-7.13M | $-6.02M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -654.49% | 0.00% | -3792.55% | -2673.78% |
| Income Tax Expense | $4.68M | $-5.93M | $-609.00K | $-619.00K | $200.00K | $327.00K | $-81.00K | $60.00K | $52.00K | $2.00K | $2.00K | $3.00K |
| Net Income | $-34.82M | $-19.72M | $-22.61M | $-19.93M | $-21.72M | $-18.59M | $-16.20M | $-17.34M | $-7.36M | $-8.07M | $-7.13M | $-6.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -654.49% | 0.00% | -3792.55% | -2673.78% |
| EPS | $-0.74 | $-0.42 | $-0.50 | $-0.53 | $-0.58 | $-0.50 | $-0.44 | $-2.30 | $-0.21 | $-0.35 | $0.00 | $-0.26 |
| EPS Diluted | $-0.74 | $-0.42 | $-0.50 | $-0.53 | $-0.58 | $-0.50 | $-0.44 | $-2.30 | $-0.21 | $-0.35 | $0.00 | $-0.26 |
| Weighted Average Shares Outstanding | 47.31M | 47.19M | 45.43M | 37.48M | 37.36M | 37.26M | 37.16M | 7.55M | 34.32M | 23.23M | - | 23.23M |
| Weighted Average Shares Outstanding Diluted | 47.31M | 47.19M | 45.43M | 37.48M | 37.36M | 37.26M | 37.16M | 7.55M | 34.32M | 23.23M | - | 23.23M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Cash and Cash Equivalents | $461.39M | $115.83M | $59.69M | $8.47M |
| Short Term Investments | $112.83M | $203.50M | $- | $18.16M |
| Cash and Short Term Investments | $574.23M | $319.32M | $59.69M | $26.63M |
| Net Receivables | $- | $2.00M | $2.00M | $2.00M |
| Inventory | $- | $- | $- | $- |
| Other Current Assets | $3.54M | $2.59M | $- | $- |
| Total Current Assets | $577.76M | $323.91M | $62.05M | $29.09M |
| Property Plant Equipment Net | $16.02M | $1.65M | $1.66M | $1.93M |
| Goodwill | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- |
| Other Non-Current Assets | $198.00K | $198.00K | $154.00K | $161.00K |
| Total Non-Current Assets | $16.22M | $1.84M | $1.81M | $2.09M |
| Other Assets | $- | $- | $- | $- |
| Total Assets | $593.98M | $325.75M | $63.86M | $31.18M |
| Account Payables | $3.08M | $1.71M | $5.09M | $1.01M |
| Short Term Debt | $1.42M | $480.00K | $98.00K | $123.00K |
| Tax Payables | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $1.12M | $863.00K |
| Other Current Liabilities | $10.65M | $8.69M | $2.98M | $1.72M |
| Total Current Liabilities | $15.15M | $10.88M | $9.29M | $3.71M |
| Long Term Debt | $11.84M | $1.92M | $- | $99.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $1.12M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $8.00K | $- | $55.87M |
| Total Non-Current Liabilities | $11.84M | $1.92M | $107.72M | $57.10M |
| Other Liabilities | $- | $- | $- | $- |
| Total Liabilities | $26.99M | $12.80M | $117.01M | $60.80M |
| Preferred Stock | $- | $325.75M | $- | $- |
| Common Stock | $5.00K | $4.00K | $- | $- |
| Retained Earnings | $-187.59M | $-103.71M | $-54.75M | $-31.01M |
| Accumulated Other Comprehensive Income Loss | $-597.00K | $-58.00K | $- | $8.00K |
| Other Total Stockholders Equity | $592.00K | $-325.70M | $1.60M | $1.38M |
| Total Stockholders Equity | $-187.59M | $-103.71M | $-53.15M | $-29.62M |
| Total Equity | $-187.59M | $-103.71M | $-53.15M | $-29.62M |
| Total Liabilities and Stockholders Equity | $-160.60M | $-90.90M | $63.86M | $31.18M |
| Minority Interest | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $-160.60M | $-90.90M | $63.86M | $31.18M |
| Total Investments | $112.83M | $203.50M | $- | $18.16M |
| Total Debt | $13.27M | $2.40M | $98.00K | $222.00K |
| Net Debt | $-448.13M | $-113.43M | $-59.59M | $-8.25M |
Balance Sheet Charts
| Breakdown | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | December 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $73.46M | $101.59M | $461.39M | $48.27M | $16.77M | $53.67M | $115.83M | $311.61M | $15.51M | $59.69M |
| Short Term Investments | $454.92M | $452.95M | $112.83M | $218.34M | $265.45M | $249.56M | $203.50M | $24.05M | $26.96M | $- |
| Cash and Short Term Investments | $528.38M | $554.55M | $574.23M | $266.61M | $282.22M | $303.23M | $319.32M | $335.66M | $42.46M | $59.69M |
| Net Receivables | $- | $- | $- | $- | $1.50M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $3.92M | $4.80M | $3.54M | $1.22M | $1.16M | $- | $- | $- | $- | $- |
| Total Current Assets | $532.30M | $559.35M | $577.76M | $267.84M | $284.88M | $307.00M | $323.91M | $340.79M | $45.07M | $62.05M |
| Property Plant Equipment Net | $16.75M | $16.06M | $16.02M | $16.49M | $16.95M | $17.41M | $1.65M | $1.40M | $1.46M | $1.66M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.62M | $198.00K | $198.00K | $669.00K | $752.00K | $198.00K | $198.00K | $198.00K | $1.50M | $154.00K |
| Total Non-Current Assets | $18.37M | $16.25M | $16.22M | $17.16M | $17.70M | $17.61M | $1.84M | $1.59M | $2.95M | $1.81M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $550.67M | $575.60M | $593.98M | $284.99M | $302.58M | $324.61M | $325.75M | $342.38M | $48.02M | $63.86M |
| Account Payables | $3.41M | $4.12M | $3.08M | $1.39M | $1.96M | $4.75M | $1.71M | $4.11M | $1.84M | $5.09M |
| Short Term Debt | $1.53M | $1.48M | $1.42M | $1.37M | $1.32M | $1.89M | $480.00K | $245.00K | $33.00K | $98.00K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.12M |
| Other Current Liabilities | $15.62M | $11.64M | $10.65M | $8.90M | $8.78M | $8.15M | $8.69M | $8.37M | $3.70M | $2.98M |
| Total Current Liabilities | $20.57M | $17.24M | $15.15M | $11.66M | $12.07M | $14.79M | $10.88M | $12.72M | $5.57M | $9.29M |
| Long Term Debt | $11.05M | $11.46M | $11.84M | $12.21M | $12.58M | $14.65M | $1.92M | $2.12M | $2.34M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $8.00K | $20.00K | $108.00M | $- |
| Total Non-Current Liabilities | $11.05M | $11.46M | $11.84M | $12.21M | $12.58M | $14.65M | $1.92M | $2.14M | $110.34M | $107.72M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $31.62M | $28.70M | $26.99M | $23.88M | $24.65M | $29.44M | $12.80M | $14.86M | $115.91M | $117.01M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $5.00K | $5.00K | $5.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $- | $- |
| Retained Earnings | $-248.06M | $-213.24M | $-187.59M | $-164.37M | $-143.82M | $-122.30M | $-103.71M | $-87.51M | $-70.18M | $-54.75M |
| Accumulated Other Comprehensive Income Loss | $2.00K | $-297.00K | $-597.00K | $-1.32M | $-1.58M | $-1.14M | $-58.00K | $-2.00K | $- | $- |
| Other Total Stockholders Equity | $767.11M | $292.00K | $592.00K | $426.80M | $423.33M | $418.60M | $54.00K | $415.03M | $2.29M | $1.60M |
| Total Stockholders Equity | $519.06M | $-213.24M | $-187.59M | $261.11M | $277.94M | $295.17M | $-103.71M | $327.52M | $-67.89M | $-53.15M |
| Total Equity | $519.06M | $-213.24M | $-187.59M | $261.11M | $277.94M | $295.17M | $-103.71M | $327.52M | $-67.89M | $-53.15M |
| Total Liabilities and Stockholders Equity | $550.67M | $-184.54M | $-160.60M | $284.99M | $302.58M | $324.61M | $-90.90M | $342.38M | $48.02M | $63.86M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $550.67M | $-184.54M | $-160.60M | $284.99M | $302.58M | $324.61M | $-90.90M | $342.38M | $48.02M | $63.86M |
| Total Investments | $454.92M | $452.95M | $112.83M | $218.34M | $265.45M | $249.56M | $203.50M | $24.05M | $26.96M | $- |
| Total Debt | $12.58M | $12.94M | $13.27M | $13.59M | $13.90M | $16.53M | $2.40M | $2.37M | $2.37M | $98.00K |
| Net Debt | $-60.88M | $-88.66M | $-448.13M | $-34.68M | $-2.87M | $-37.13M | $-113.43M | $-309.24M | $-13.13M | $-59.59M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Net Income | $-83.89M | $-48.96M | $-23.74M | $-12.94M |
| Depreciation and Amortization | $2.42M | $661.00K | $697.00K | $706.00K |
| Deferred Income Tax | $- | $1.67M | $- | $- |
| Stock Based Compensation | $12.82M | $5.58M | $556.00K | $529.00K |
| Change in Working Capital | $2.64M | $1.65M | $1.66M | $-4.65M |
| Accounts Receivables | $1.50M | $- | $- | $- |
| Inventory | $- | $- | $- | $- |
| Accounts Payables | $1.33M | $-772.00K | $1.41M | $289.00K |
| Other Working Capital | $-191.00K | $2.42M | $252.00K | $-4.94M |
| Other Non Cash Items | $1.67M | $107.00K | $144.00K | $54.00K |
| Net Cash Provided by Operating Activities | $-64.32M | $-39.29M | $-20.68M | $-16.30M |
| Investments in Property Plant and Equipment | $-2.24M | $-718.00K | $-148.00K | $-981.00K |
| Acquisitions Net | $- | $- | $- | $- |
| Purchases of Investments | $-139.25M | $-218.47M | $-3.65M | $-39.77M |
| Sales Maturities of Investments | $228.98M | $14.56M | $21.80M | $21.62M |
| Other Investing Activities | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $87.49M | $-204.62M | $18.00M | $-19.13M |
| Debt Repayment | $- | $- | $- | $- |
| Common Stock Issued | $323.71M | $214.71M | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- |
| Other Financing Activities | $322.25M | $300.25M | $53.90M | $-278.00K |
| Net Cash Used Provided by Financing Activities | $322.25M | $300.25M | $53.90M | $-278.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- |
| Net Change in Cash | $345.42M | $56.34M | $51.22M | $-35.71M |
| Cash at End of Period | $461.59M | $116.17M | $59.84M | $8.62M |
| Cash at Beginning of Period | $116.17M | $59.84M | $8.62M | $44.33M |
| Operating Cash Flow | $-64.32M | $-39.29M | $-20.68M | $-16.30M |
| Capital Expenditure | $-2.24M | $-718.00K | $-148.00K | $-981.00K |
| Free Cash Flow | $-66.56M | $-40.01M | $-20.83M | $-17.28M |
Cash Flow Charts
| Breakdown | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-34.82M | $-25.65M | $-23.22M | $-20.55M | $-21.52M | $-18.59M | $-16.20M | $-17.34M | $-7.36M | $-8.07M | $-7.13M | $-6.02M |
| Depreciation and Amortization | $687.00K | $630.00K | $609.00K | $595.00K | $700.00K | $519.00K | $156.00K | $146.00K | $179.00K | $180.00K | $172.00K | $169.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- | $329.00K | $135.00K | $1.38M | $- | $- | $- | $- |
| Stock Based Compensation | $5.50M | $4.89M | $3.34M | $3.46M | $4.21M | $1.81M | $1.68M | $3.16M | $396.00K | $347.00K | $150.00K | $149.00K |
| Change in Working Capital | $2.75M | $60.00K | $1.09M | $1.07M | $-1.26M | $1.74M | $-217.00K | $3.70M | $-1.39M | $-451.00K | $1.18M | $549.00K |
| Accounts Receivables | $- | $- | $- | $1.50M | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-119.00K | $472.00K | $1.62M | $-574.00K | $-2.77M | $3.05M | $-2.13M | $2.06M | $-398.00K | $-294.00K | $1.07M | $140.00K |
| Other Working Capital | $2.87M | $-472.00K | $-529.00K | $142.00K | $1.51M | $-1.31M | $1.92M | $1.65M | $-991.00K | $-157.00K | $105.00K | $409.00K |
| Other Non Cash Items | $-2.70M | $-2.37M | $288.00K | $98.00K | $930.00K | $29.00K | $164.00K | $1.40M | $219.00K | $-8.00K | $52.00K | $38.00K |
| Net Cash Provided by Operating Activities | $-28.58M | $-22.44M | $-17.89M | $-15.32M | $-16.94M | $-14.16M | $-14.41M | $-8.92M | $-7.96M | $-8.00M | $-5.58M | $-5.11M |
| Investments in Property Plant and Equipment | $-1.83M | $-202.00K | $-437.00K | $-524.00K | $-891.00K | $-385.00K | $-196.00K | $-121.00K | $-36.00K | $-365.00K | $-17.00K | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-53.96M | $-397.72M | $-44.61M | $-29.14M | $-44.61M | $-65.51M | $-191.50M | $-15.00K | $-2.87M | $-24.08M | $- | $-1.00K |
| Sales Maturities of Investments | $55.00M | $60.27M | $106.42M | $76.50M | $28.06M | $18.00M | $11.87M | $2.70M | $- | $- | $- | $3.00M |
| Other Investing Activities | $- | $- | $44.61M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-792.00K | $-337.65M | $105.98M | $46.84M | $-17.44M | $-47.89M | $-179.83M | $2.56M | $-2.91M | $-24.45M | $-17.00K | $3.00M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $351.00K | $323.71M | $- | $- | $- | $-1.48M | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $4.83B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-4.83B | $292.00K | $325.04M | $-8.00K | $-2.67M | $-108.00K | $-1.54M | $302.46M | $1.85M | $-2.52M | $54.32M | $-361.00K |
| Net Cash Used Provided by Financing Activities | $1.24M | $292.00K | $325.04M | $-8.00K | $-2.67M | $-108.00K | $-1.54M | $302.46M | $1.85M | $-2.52M | $54.32M | $-361.00K |
| Effect of Forex Changes on Cash | $4.86B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-28.13M | $-359.80M | $413.12M | $31.50M | $-37.05M | $-62.16M | $-195.78M | $296.11M | $-9.02M | $-34.97M | $48.72M | $-2.47M |
| Cash at End of Period | $73.66M | $101.79M | $461.59M | $48.47M | $16.96M | $54.02M | $116.17M | $311.96M | $15.85M | $24.87M | $59.84M | $11.12M |
| Cash at Beginning of Period | $101.79M | $461.59M | $48.47M | $16.96M | $54.02M | $116.17M | $311.96M | $15.85M | $24.87M | $59.84M | $11.12M | $13.59M |
| Operating Cash Flow | $-28.58M | $-22.44M | $-17.89M | $-15.32M | $-16.94M | $-14.16M | $-14.41M | $-8.92M | $-7.96M | $-8.00M | $-5.58M | $-5.11M |
| Capital Expenditure | $-1.83M | $-202.00K | $-437.00K | $-524.00K | $-891.00K | $-385.00K | $-196.00K | $-121.00K | $-36.00K | $-365.00K | $-17.00K | $- |
| Free Cash Flow | $-30.41M | $-22.64M | $-18.33M | $-15.85M | $-17.83M | $-14.55M | $-14.61M | $-9.04M | $-7.99M | $-8.36M | $-5.59M | $-5.11M |
DICE Therapeutics Dividends
Explore DICE Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
DICE Therapeutics News
Read the latest news about DICE Therapeutics, including recent articles, headlines, and updates.
Lilly Completes Acquisition of DICE Therapeutics
INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.
Lilly Announces Extension of Tender Offer to Acquire DICE
INDIANAPOLIS , July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ: DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire one minute past 11:59 p.m.
DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE Therapeutics, Inc. (NasdaqGM: DICE) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of DICE will receive $48.00 in cash for each share of DICE that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.
ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics
Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline, specifically targeting immune disease-related treatments.
Eli Lilly takeover of DICE Therapeutics ‘makes strategic sense,' says broker
Eli Lilly and Co (NYSE:LLY)'s $2.4 billion acquisition of DICE Therapeutics “makes strategic sense,” bolstering the global pharmaceutical company's presence in immunology, analysts at UBS said in a note on Wednesday. UBS, which has a ‘Buy' rating and a 12-month price target of $498 for Eli Lilly, noted that the acquisition provides two oral IL-17 inhibitors DC-806 and DC-853, as well as additional pipeline opportunities to the company's profile.
DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE Therapeutics, Inc. (NasdaqGM: DICE) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of DICE will receive $48.00 in cash for each share of DICE that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.
Shares of Eli Lilly, Dice Therapeutics Gain on Acquisition Announcement
Looking to enhance its product portfolio for immune-related diseases, an area where it has lagged behind the competition, Eli Lilly & Co. ( LLY , Financial) announced on Tuesday it is acquiring Dice Therapeutics Inc. ( DICE , Financial) in a deal valued at $2.4 billion.
Options Traders Blast Dice Therapeutics Stock After Buyout
Dice Therapeutics Inc (NASDAQ:DICE) was last seen up 37.6% to trade at a fresh all-time high of $46.56, after Eli Lilly (LLY) revealed it will buy the immunology drug maker for roughly $2.4 billion , or $48 per share, in an all-cash deal that is a 40% premium to DICE's last close.
Why Is Dice Therapeutics (DICE) Stock Up 38% Today?
Dice Therapeutics (NASDAQ: DICE ) stock is surging higher on Tuesday after Eli Lilly (NYSE: LLY ) announced plans to acquire the biopharmaceutical company. According to a news release, Eli Lilly is paying $48 per share to acquire all outstanding shares of DICE stock through a tender offer.
Eli Lilly sends DICE Therapeutics' shares soaring with $2.4B takeover
Eli Lilly and Co (NYSE:LLY) said it has signed a definitive agreement to acquire DICE Therapeutics for $2.4 billion, sending shares of the biopharmaceutical company higher in pre-market trade. Under the deal, which has been approved by the boards of both companies, Lilly said it will commence a tender offer to acquire all outstanding shares of DICE for $48 per share in cash, a 42% premium to its previous closing price.
Dice Therapeutics rallies as it agrees to be bought by Lilly
Dice Therapeutics Inc. DICE stock is up by 40% in premarket trades Tuesday after it agreed to be purchased by Eli Lilly & Co. LLY for $48 a share in a deal that values the immunology company at about $2.4 billion. The price values Dice at a 40% premium over the 30-day, volume-weighted average trading price of its stock as of June 16.
DICE Therapeutics psoriasis treatment has blockbuster potential, analysts say
Canaccord Genuity (TSX:CF, LSE:CF) analysts have initiated coverage of DICE Therapeutics, Inc, a biopharmaceutical company focused on treating chronic autoimmune and inflammatory diseases, Monday with a ‘Buy' rating and a 12-month target price of $71 per share, noting the company's lead compound DC-806 for treating plaque psoriasis (PsO) has “blockbuster potential”. The analysts wrote that they believe DICE is poised for clinical success, given the company's R&D strategy of selecting drug targets that are: 1) proven to be effective for indications with high prevalence; 2) clinically and commercially validated by approved biologics; and 3) known to have structural features that support potent small molecule binding.
DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
SOUTH SAN FRANCISCO, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today announced management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 4:00 p.m. ET.
DICE Therapeutics to Participate at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced management will participate at the following investor conferences:
DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PST / 3:00 p.m. EST.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for DICE.